keyword
MENU ▼
Read by QxMD icon Read
search

Risperidone

keyword
https://www.readbyqxmd.com/read/29453686/antipsychotic-prescribing-and-safety-monitoring-practices-in-children-and-youth-a-population-based-study-in-alberta-canada
#1
Wenxin Chen, Monica Cepoiu-Martin, Antonia Stang, Diane Duncan, Chris Symonds, Lara Cooke, Tamara Pringsheim
BACKGROUND AND OBJECTIVE: Antipsychotic medication use has steadily increased in Canada, with an expansion in the profile of users and the diagnoses for which they are used. The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended. The objectives of this study were to determine the most common diagnoses associated with antipsychotic use in children in Alberta, Canada and the proportion who receive recommended laboratory tests for adverse effects...
February 16, 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29441581/genetic-polymorphisms-of-htr2c-lep-and-lepr-on-metabolic-syndromes-in-patients-treated-with-atypical-antipsychotic-drugs
#2
Apichaya Puangpetch, Weerapon Unaharassamee, Napa Jiratjintana, Napatrupron Koomdee, Chonlaphat Sukasem
OBJECTIVE: Single nucleotide polymorphisms in serotonin 2C receptor (HTR2C), leptin (LEP), and leptin receptor (LEPR) genes are reportedly associated with the presence of metabolic syndrome (MS). We investigated whether HTR2C:rs518147 (-697G/C), rs12836771 (A/G), LEP: rs7799039 (-2548G/A) and LEPR:rs1137101 (668A/G) are related to MS in psychotic disorder patients treated with atypical antipsychotics. METHODS: A cross-sectional study including 200 patients was conducted; genetic polymorphisms in HTR2C (rs518147 and rs12836771), LEP (rs7799039) and LEPR (rs1137101) were genotyped...
February 13, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29441189/neuroleptic-malignant-syndrome-a-case-responding-to-electroconvulsive-therapy-plus-bupropion
#3
Quintí Foguet-Boreu, Montse Coll-Negre, Montse Serra-Millàs, Miquel Cavalleria-Verdaguer
Neuroleptic malignant syndrome (NMS) is a severe motor syndrome occurring as a consequence of neuroleptic treatment. We present a case of a 67-year-old Caucasian woman with a history of a major depressive disorder with psychotic features. During her third hospital admission, symptoms of autonomic instability, hyperpyrexia, severe extrapyramidal side effects, and delirium appeared, suggesting NMS due to concomitant treatment with risperidone and quetiapine, among other drugs. Despite several consecutive pharmacological treatments (lorazepam, bromocriptine and amantadine) and prompt initiation of electroconvulsive therapy (ECT), clinical improvement was observed only after combining bupropion with ECT...
January 8, 2018: Clinics and Practice
https://www.readbyqxmd.com/read/29439327/stabilized-low-n-amyloid-%C3%AE-oligomers-induce-robust-novel-object-recognition-deficits-associated-with-inflammatory-synaptic-and-gabaergic-dysfunction-in-the-rat
#4
William Watremez, Joshua Jackson, Bushra Almari, Samantha L McLean, Ben Grayson, Joanna C Neill, Nicolas Fischer, Ahmad Allouche, Violette Koziel, Thierry Pillot, Michael K Harte
BACKGROUND: With current treatments for Alzheimer's disease (AD) only providing temporary symptomatic benefits, disease modifying drugs are urgently required. This approach relies on improved understanding of the early pathophysiology of AD. A new hypothesis has emerged, in which early memory loss is considered a synapse failure caused by soluble amyloid-β oligomers (Aβo). These small soluble Aβo, which precede the formation of larger fibrillar assemblies, may be the main cause of early AD pathologies...
2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29432503/therapeutic-drug-monitoring-of-atypical-antipsychotics
#5
REVIEW
Anna Emilia Urban, Wiesław Jerzy Cubała
The paper presents an overview and analysis of the results of research on therapeutic ranges of concentrations and receptor occupancy, mainly D2 receptors, in the treatment with some atypical antipsychotic drugs. Amisulpride, aripiprazole, clozapine, quetiapine, olanzapine, risperidone, paliperidone, sertindole, and ziprasidone were taken into account. The benefits of therapeutic drug monitoring to optimize the effectiveness of treatment and avoid side effects or toxicity were shown. The safety of patients, with the possibility to use the lowest effective dose, is an undoubted profit of TDM...
December 30, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/29432331/evaluation-of-the-effect-of-fluvoxamine-in-patients-with-schizophrenia-under-risperidone-treatment-a-clinical-trial
#6
Alireza Haji Seyed Javadi, Ali Akbar Shafikhani, Seyed Mohsen Zamir, Zahra Farzane Khanshir
PURPOSE/BACKGROUND: The effectiveness of selective-serotonin reuptake inhibitors in the improvement of schizophrenia is a controversial issue. The aim of this study was to evaluate the effect of fluvoxamine on the symptoms of schizophrenia including positive and negative symptoms, cognitive impairment, and quality of life. METHODS/PROCEDURES: This clinical trial was performed on 68 patients with chronic schizophrenia, treated with risperidone at 22 Bahman Hospital of Qazvin, Iran during 2015 to 2016...
February 9, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29430641/comparative-effect-of-antipsychotics-on-risk-of-self-harm-among-patients-with-schizophrenia
#7
C-H Ma, S-S Chang, H-J Tsai, S S-F Gau, I-M Chen, S-C Liao, Y-L Chien, M H Hsieh, C-S Wu
OBJECTIVE: To investigate the association of different antipsychotic treatments with hospitalization due to self-harm among patients with schizophrenia. METHOD: This retrospective cohort study was based on Taiwan's universal health insurance database. Patients aged 15-45 years with a newly diagnosed schizophrenic disorder in 2001-2012 were included. The study outcome was the first hospitalization due to self-harm or undetermined injury after the diagnosis of schizophrenic disorders...
February 11, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29429138/qtc-prolongation-in-short-term-treatment-of-schizophrenia-patients-effects-of-different-antipsychotics-and-genetic-factors
#8
Ilja Spellmann, Matthias A Reinhard, Diana Veverka, Peter Zill, Michael Obermeier, Sandra Dehning, Rebecca Schennach, Norbert Müller, Hans-Jürgen Möller, Michael Riedel, Richard Musil
Antipsychotics are effective in treating schizophrenia but may lead to a higher cardiovascular risk due to QTc prolongation. Besides drugs, genetic and clinical factors may contribute to QTc prolongation. The aim of this study is to examine the effect of candidate genes known for QTc prolongation and their interaction with common antipsychotics. Thus, 199 patients were genotyped for nine polymorphisms in KCNQ1, KCNH2, SCN5A, LOC10537879, LOC101927066, NOS1AP and NUBPL. QTc interval duration was measured before treatment and weekly for 5 weeks while being treated with risperidone, quetiapine, olanzapine, amisulpride, aripiprazole and haloperidol in monotherapy...
February 10, 2018: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29427913/l-carnosine-as-an-add-on-to-risperidone-for-treatment-of-negative-symptoms-in-patients-with-stable-schizophrenia-a-double-blind-randomized-placebo-controlled-trial
#9
Alireza Ghajar, Mohammad-Reza Khoaie-Ardakani, Zahara Shahmoradi, Amir-Reza Alavi, Mohsen Afarideh, Mohammad-Reza Shalbafan, Maryam Ghazizadeh-Hashemi, Shahin Akhondzadeh
Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted. Sixty-three patients with chronic schizophrenia, who were clinically stable on a stable dose of risperidone, entered the study. The patients were randomly assigned to l-carnosine (2 gr/day in two divided doses) or placebo for eight weeks. The patients were assessed using the positive and negative syndrome scale (PANSS), extrapyramidal symptom rating scale (ESRS), and Hamilton depression rating scale (HDRS) during the study course...
February 3, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29426531/a-water-compatible-magnetic-molecularly-imprinted-polymer-for-the-selective-extraction-of-risperidone-and-9-hydroxyrisperidone-from-human-urine
#10
Wen-Hua Ji, Yu-Shuang Guo, Xiao Wang, D-S Guo
An accurate, rapid, and sensitive method for the determination of risperidone and 9-hydroxyrisperidone in urine samples was developed by combining water-compatible magnetic molecularly imprinted solid-phase extraction with high performance liquid chromatography. Several variables relating to the efficiency of magnetic solid phase extraction were optimized, including the amount of adsorbent, adsorption time, type of elution solvent, and desorption time. The analytical performance of this method was validated under the optimized conditions...
May 1, 2018: Talanta
https://www.readbyqxmd.com/read/29425796/doxycycline-prevents-and-reverses-schizophrenic-like-behaviors-induced-by-ketamine-in-mice-via-modulation-of-oxidative-nitrergic-and-cholinergic-pathways
#11
Benneth Ben-Azu, Itivere Adrian Omogbiya, Adegbuyi Oladele Aderibigbe, Solomon Umukoro, Abayomi Mayowa Ajayi, Ezekiel O Iwalewa
The involvement of oxidative/nitrosative stress, cholinergic and inflammatory pathways have been reported to contribute to the pathophysiology of schizophrenia, a debilitating neuropsychiatric disorder. Our previous studies have shown that doxycycline (DOX), a notable member of tetracyclines with proven antioxidant and anti-inflammatory properties, attenuated psychotic-like behaviors induced by apomophine and ketamine (KET) in mice. This present study was designed to further evaluate in detail the ability of DOX and its combination with risperidone (RIS) to prevent and reverse KET-induced schizophrenic-like behaviors and the role of oxidative/nitrosative and cholinergic pathways in mice...
February 6, 2018: Brain Research Bulletin
https://www.readbyqxmd.com/read/29424804/no-effect-of-adjunctive-minocycline-treatment-on-body-metabolism-in-patients-with-schizophrenia
#12
Fang Liu, Liqin Xie, Bingkui Zhang, Ye Ruan, Yong Zeng, XiuFeng Xu, Jingping Zhao, Xiaoduo Fan
PURPOSE/BACKGROUND: This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia. METHODS/PROCEDURES: Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia and had been on stable dose of risperidone for at least 4 weeks. In a 16-week randomized, double-blind, placebo-controlled study, subjects received either minocycline (200 mg/d) or placebo...
February 8, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29423863/a-framework-for-2-stage-global-sensitivity-analysis-of-gastroplus%C3%A2-compartmental-models
#13
Megerle L Scherholz, James Forder, Ioannis P Androulakis
Parameter sensitivity and uncertainty analysis for physiologically based pharmacokinetic (PBPK) models are becoming an important consideration for regulatory submissions, requiring further evaluation to establish the need for global sensitivity analysis. To demonstrate the benefits of an extensive analysis, global sensitivity was implemented for the GastroPlus™ model, a well-known commercially available platform, using four example drugs: acetaminophen, risperidone, atenolol, and furosemide. The capabilities of GastroPlus were expanded by developing an integrated framework to automate the GastroPlus graphical user interface with AutoIt and for execution of the sensitivity analysis in MATLAB®...
February 8, 2018: Journal of Pharmacokinetics and Pharmacodynamics
https://www.readbyqxmd.com/read/29420868/pharmacokinetics-and-safety-of-risperidone-subcutaneous-implants-in-stable-patients-with-schizophrenia
#14
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz
A subcutaneous risperidone implant (RI) formulation was developed to improve medication adherence in schizophrenia. Two phase 1 studies were conducted to evaluate the pharmacokinetics of RI in adult patients with schizophrenia. In study 1, all subjects were stable on 4 mg oral risperidone; subsequently, the first subject received 375 mg RI for 1 month, and the remaining subjects received 375 mg RI for 3 months. In study 2, all subjects were stable on oral risperidone 4 mg, 6 mg, or 8 mg and subsequently received RI 480 mg, 720 mg, or 960 mg, respectively, for 6 months...
February 8, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29409162/antipsychotic-reduction-and-or-cessation-and-antipsychotics-as-specific-treatments-for-tardive-dyskinesia
#15
REVIEW
Hanna Bergman, John Rathbone, Vivek Agarwal, Karla Soares-Weiser
BACKGROUND: Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29406406/two-year-effectiveness-of-risperidone-and-aripiprazole-in-the-maintenance-treatment-of-patients-with-recent-onset-or-chronic-schizophrenia-and-related-psychotic-disorders-a-retrospective-multicenter-study
#16
Yusaku Yoshimura, Toshihiko Takeda, Yoshiki Kishi, Toshiki Harada, Akira Nomura, Kenji Washida, Bunta Yoshimura, Kojiro Sato, Yuji Yada, Shozo Aoki
This study aimed to assess the comparative effectiveness of risperidone (RIS) versus aripiprazole (ARP) in patients with recent-onset or chronic schizophrenia during maintenance treatment and to examine the interaction between illness duration and the effectiveness of the treatment. All adult patients with schizophrenia and related disorders discharged from four psychiatric hospitals between 2006 and 2012 were screened and the 2-year continuation rates of monotherapy using RIS or ARP after discharge were examined retrospectively...
February 5, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29404931/genotyping-as-a-key-element-of-sample-size-optimization-in-bioequivalence-of-risperidone-tablets
#17
Ying Chen, Yang Deng, Miao Yan, Zhenyan Hou, Yao Li, Bikui Zhang, Hualin Cai
BACKGROUND AND OBJECTIVES: Risperidone is a derivative of benzisoxazole and is widely used for schizophrenia and other psychiatric illnesses in both adults and children. Previous studies have confirmed that it is a highly variable drug (within-subject variability ≥ 30%). To reduce the large sample size required for bioequivalence researches on highly variable drugs, a role for genotyping in the design of the bioequivalence study was employed. METHODS: A randomized, open-label, two-period crossover study was adopted: 20 subjects with specific genotypes carrying cytochrome P450 (CYP) 2D6*10 were randomized to two groups to receive a single oral dose of trial formulation or reference formulation with a 2-week washout period...
February 5, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29403128/add-on-aripiprazole-for-atypical-antipsychotic-induced-clinically-significant-hyperprolactinemia
#18
Dhanya Raveendranthan, Naren P Rao, Mukund G Rao, Ajish G Mangot, Shivaram Varambally, Muralidharan Kesavan, Ganesan Venkatasubramanian, Bangalore N Gangadhar
Background: Antipsychotic treatment-induced hyperprolactinemia is a highly distressing and disabling side effect for patients. The use of add-on aripiprazole has been identified as a possible treatment strategy in this situation. However, data on prolactin changes with add-on aripiprazole in a real-world naturalistic clinical setting from India are sparse. Materials and Methods: The retrospective chart review was conducted at the specialty metabolic clinic at the National Institute of Mental Health and Neurosciences, Bengaluru, India...
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29401113/clozapine-for-treatment-refractory-behavioral-disturbance-in-dementia
#19
Andreea Teodorescu, Lorena Dima, Petru Ifteni, Liliana M Rogozea
BACKGROUND: Behavioral and psychological symptoms in dementia significantly contribute to caregiver burden and impose patient hospitalization. The goal of treatment of admitted patients is the rapid remission of symptoms to allow their return to home as soon as possible. Intervention requires an intrusive approach with parenteral treatment and physical restraints, with a negative emotional impact on patients and their families. Despite the large utilization of antipsychotics for behavioral and psychological symptoms, there is no antipsychotic approved by the Food and Drug Administration for agitation in dementia...
January 31, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29398934/pharmacotherapy-of-emotional-and-behavioral-symptoms-associated-with-autism-spectrum-disorder-in-children-and-adolescents
#20
Ekaterina Stepanova, Susannah Dowling, Molly Phelps, Robert L Findling
Autism spectrum disorder (ASD) is characterized by impairment in social communication and restricted patterns of behavior. Although there is no pharmacological treatment approved by the US Food and Drug Administration (FDA) for the core symptoms of ASD, there is mounting support in the literature for the management of behavioral symptoms associated with this developmental disorder, in particular, irritability and hyperactivity. Aripiprazole and risperidone are currently approved by the FDA for the treatment of irritability in youth with ASD...
December 2017: Dialogues in Clinical Neuroscience
keyword
keyword
4837
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"